Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
Investor insights
Funding rounds participated in
$215M sweet spot round size
Investor type
Basic info
Industry
Sectors
Funding rounds raised
Total raised
$215M
from 3 investors over 1 rounds
Metsera raised $215M on December 13, 2024
Investors: Wellington Management, Venrock Healthcare Capital Partners and + 12 Other investors